Trial Profile
Clinical development for the evaluation of targeted treatment for metastatic renal cancer - PETTO.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2012
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PETTO
- 06 Aug 2011 New trial record